Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Clinical diagnoses can be broad descriptions, but today's test results can help better understand the condition as well as target treatment. Cancer is a good example in which personalised medicine can help decide which molecular targeted therapy is most appropriate.

Q: What is personalised medicine?

Jenny Taylor: Personalised medicine is about making the treatment a patient receives very relevant for their own specific condition. Clinical diagnoses can be quite broad umbrella descriptions and personalised medicine aims to introduce and integrate a lot of different test results to ensure that the particular condition a patient has is understood at a variety of levels and the therapy or clinical management is targeted accordingly.

Q: How can scientists tailor treatments for an individual patient?

JT: Cancer is a good example of where scientists and clinicians are already tailoring treatment. Previously when a patient received a diagnosis of cancer, surgery to remove their cancer and then chemotherapy was prescribed, and maybe radiotherapy too. Chemotherapy and radiotherapy are very toxic treatments and the emergence of new molecular therapies in cancer against particular molecular targets has really revolutionised the field but we have to know the particular aberration or mutation in a patient's tumour in order to decide which of those therapies would be most appropriate for that particular patient.

Q: Can you give an example of a personalised medicine approach?

JT: Following on from the theme of cancer, one of the approaches that we've taken is to develop these gene panels where we can sequence the genes that are known to be involved in different cancers and identify the mutations that are present in any given patient's tumour. Once we have that knowledge we can then identify which of the molecular targeted therapies they should receive.

Q: What are the most important lines of research that have developed in the past five or ten years?

JT: Genomics has had a very exciting, a really cutting edge time, revolutionising not just the research field, but the whole application of genomics to clinical medicine. We can now test multiple different genes to see whether there are mutations or changes in a patient's DNA. Where previously we used to do that one gene at a time, now we can look at several in parallel and increasingly whole genome sequencing. So genomics has had a huge impact in this arena.

Q: Why does your line of research matter and why should we put money into it?

JT: Our line of research is very much focused on the discovery of novel genes for human disease, but also the development of genomic technologies that will allow us to bring new tests into the clinic for use in diagnosing patients. It is clearly very important, not just for understanding the mechanisms of disease, which the discovery of new genes will help with, but also for ensuring that patients are going to benefit from those discoveries and that the results aren't lost in a journal, but are actually developed for people here and now.

Q: How does your research fit into translational medicine within the Department?

JT: Our research is very closely integrated with the translational medicine within the Department and is also part of the Oxford Biomedical Research Programme, which is a translational programme. We've got a genomic medicine theme, but by being based in the Wellcome Trust Centre of Human Genetics, we can look at the genetics discoveries that are arising from Principle Investigators in the Centre. We work very closely with the Biomedical Research Programme and with the Oxford Universities Hospitals Trust to make sure that these research discoveries are translated into clinical benefits. We are the conduit for making sure that translation from research to the bedside is actually happening.

Jenny Taylor

Genomic Medicine Theme

Professor Jenny Taylor is the Programme Director for the Genomic Medicine Theme at the Wellcome Trust Centre for Human Genetics. Her research aims to bridge the gap between genetics research and the use of its discoveries in diagnosis or treatment of medical conditions.

More podcasts related to Cancer

Raghib Ali: INDOX Cancer Research Network

INDOX is a collaboration between Oxford and twelve leading cancer centres in India. It aims to develop effective and affordable cancer treatments in low and middle income countries, to improve the early detection of cancer, and to reduce the incidence of cancer by establishing the population specific risk factors.

Vincenzo Cerundolo: Cancer immunology

The development of therapeutic vaccines is more challenging. Current lines of research include the development of antibodies blocking inhibitory T cell signals, and the characterisation of adjuvants.

Anna Gloyn: Genetics and Diabetes

Predictions suggest that by 2030, 366 million people worldwide will be affected by diabetes, a disease which already uses 10% of the NHS budget. Continued breakthroughs in the area of genetics related to different types of diabetes enable better diagnosis and treatment for patients and identify novel pathways that can be targeted for therapeutic interventions.

David Jackson: The Lymphatic System in Immunity and Cancer

Our lymphatic system protects us against pathogens: it collects micro-organisms and carries them to the lymph nodes where they will meet and activate T cells and B cells. Cancer cells also migrate to the lymph nodes, but instead of activating the immune system they actually suppress it. A better understanding of these mechanisms might help us better control the spread of tumours, and also block unwanted immune responses in autoimmune diseases, block tissue rejection and make vaccines more effective.

Tim Key: Role of Lifestyle and Diet in Cancer

We know that although smoking is still the most important cause of cancer, obesity and high intakes of alcohol increase the risk for several types of cancer. The role of diet in the development of cancer is much less clear, but there is a lot of evidence suggesting that diet does matter.

Erika Mancini: Chromatin Remodelling

Chromatin plays an important role in the regulation of gene expression. The movement of nucleosomes, packing and unpacking DNA, is governed by chromatin remodelling ATPases. Malfunctions in the regulation of chromatin structure often leads to complex multi-system diseases and cancer, notably leukemia.

Diabetes and Genomics by Mark McCarthy

Diabetes and obesity are both major challenges for global healthcare, with the social, health and economic costs over the next fifty years being in the ‘trillions’ of dollars. Genetics is one of the more important tools for developing a systematic understanding of the disease and how best to treat it in different patients.

Silvia Paracchini: Dyslexia and Genetics

Dyslexia is an impairment in learning to read that affects up to 10% of children; it can have profound effects on an individual life. Dyslexia has an important genetic component; candidate genes control important stages during foetal brain development. Understanding the biology of dyslexia could help us design more effective diagnostic criteria and treatment plans.

Patrick Pollard: Cancer Metabolism

Dr Pollard’s work is focused on a form of kidney cancer for which no effective therapy exists once it metastasizes. By integrating analyses of these cancer cells and novel models he hopes to provide insights into altered cancer metabolism and a real, innovative route into the design of therapies for various cancers.

Claire Palles: Gastrointestinal cancers

The gastrointestinal track is responsible for more cancers than any other system. A condition called Barrett's oesophagus, characterised by a change in the cells lining the oesophagus, can lead to oesophageal adenocarcinoma. Only few people with Barrett's oesophagus will go on to develop cancer, and genome sequencing studies aim to identify genetic risk factors and therefore better target high-risk patients.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.